4th mRNA Process Development & CMC Summit: September 23 – 25
LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the 2025 mRNA Process Development & CMC Summit, September 23 – 25 in Boston, MA.
Blog
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing STONY BROOK, N.Y. September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: LineaRx will present its Linea™ IVT […]
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
– Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA – STONY BROOK, N.Y., September 17, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity […]
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination STONY BROOK, N.Y. – July 29, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 – 31, 2024, in Boston. The poster […]
Reduction of dsRNA Contamination in High-Yield mRNA Production
via use of the Linea IVT Platform | Chemically-Modified, Enzymatically-Produced IVT Templates + a Next-Generation RNA Polymerase Yuhua Sun | Huan Dong | Qiang Zhao | Finly Philip | Clay Shorrock | Aaron Chung | James Hayward Enter information below to download our poster!
Applied DNA and Alphazyme Conclude Linea™ RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea™ IVT Platform Economics
Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, N.Y., and JUPITER, FL – June 20, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA […]
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
– Patent covers the Composition of the Company’s Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform – – Patent Application Also Currently Pending in Key International Markets – STONY BROOK, N.Y., – June 5, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA […]
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
STONY BROOK, N.Y., and PRAGUE, Czechia – May 13, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and […]
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days STONY BROOK, N.Y., April 25, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT […]
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea™ RNAP, Progresses Towards GMP Linea™ IVT Production Start
Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods Project Slated For Completion Coincident with Company’s Planned Initiation of GMP Manufacturing for Linea™ DNA IVT Templates STONY BROOK, N.Y., and JUPITER, F.L. March 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA […]